| scholarly article | Q13442814 |
| P50 | author | James David West | Q54640899 |
| P2093 | author name string | Koichiro Tatsumi | |
| Nobuhiro Tanabe | |||
| Yuji Tada | |||
| Tadashi Yasuda | |||
| P2860 | cites work | Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. | Q51025574 |
| Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH. | Q51760564 | ||
| Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension | Q55670914 | ||
| Dysfunctional Smad Signaling Contributes to Abnormal Smooth Muscle Cell Proliferation in Familial Pulmonary Arterial Hypertension | Q57149168 | ||
| Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice | Q79495174 | ||
| Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension | Q24298704 | ||
| Signal transduction of bone morphogenetic protein receptors | Q24302298 | ||
| Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1 | Q24675335 | ||
| The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase | Q28117594 | ||
| Bone morphogenetic protein receptors and signal transduction | Q28258965 | ||
| Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho | Q29614250 | ||
| Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase | Q29615195 | ||
| Non-Smad pathways in TGF-beta signaling | Q29620040 | ||
| Primary pulmonary hypertension. A national prospective study | Q33169642 | ||
| Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene | Q34142690 | ||
| Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension | Q34272849 | ||
| Physiologic and molecular consequences of endothelial Bmpr2 mutation | Q35121379 | ||
| Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension | Q35583736 | ||
| Regulation of smooth muscle calcium sensitivity: KCl as a calcium-sensitizing stimulus | Q36068027 | ||
| Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? | Q36634716 | ||
| Reactive oxygen species mediate RhoA/Rho kinase-induced Ca2+ sensitization in pulmonary vascular smooth muscle following chronic hypoxia | Q36877325 | ||
| Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension | Q36964914 | ||
| Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions | Q36977330 | ||
| Control of transforming growth factor beta signal transduction by small GTPases. | Q37505210 | ||
| Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension | Q39640769 | ||
| Transforming growth factor-beta1-induced expression of smooth muscle marker genes involves activation of PKN and p38 MAPK. | Q40404500 | ||
| Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. | Q40465480 | ||
| Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension | Q41964119 | ||
| A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes | Q42819347 | ||
| Rho-kinase activation is involved in hypoxia-induced pulmonary vasoconstriction | Q43802280 | ||
| Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor | Q43952396 | ||
| Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats | Q44690023 | ||
| Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle | Q44805539 | ||
| Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease | Q46157334 | ||
| BMP signaling controls PASMC KV channel expression in vitro and in vivo | Q46844207 | ||
| Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension | Q46910317 | ||
| P433 | issue | 5 | |
| P921 | main subject | arterial hypertension | Q41861 |
| morphogenesis | Q815547 | ||
| pulmonary hypertension | Q1128595 | ||
| P304 | page(s) | L667-74 | |
| P577 | publication date | 2011-08-19 | |
| P1433 | published in | American Journal of Physiology - Lung Cellular and Molecular Physiology | Q4352992 |
| P1476 | title | Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene | |
| P478 | volume | 301 |
| Q30544892 | A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects |
| Q27026643 | A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? |
| Q37104263 | A potential role for insulin resistance in experimental pulmonary hypertension |
| Q38078369 | A process-based review of mouse models of pulmonary hypertension |
| Q36847595 | Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension |
| Q35850232 | Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension |
| Q60925993 | Endothelial cells from pulmonary endarterectomy specimens possess a high angiogenic potential and express high levels of hepatocyte growth factor |
| Q36421287 | Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism |
| Q37688533 | Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. |
| Q38741321 | Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways |
| Q33806083 | Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension |
| Q88542694 | JNK2 regulates vascular remodeling in pulmonary hypertension |
| Q27009717 | Microvessel mechanobiology in pulmonary arterial hypertension: cause and effect |
| Q33689573 | Molecular and functional characterization of the BMPR2 gene in Pulmonary Arterial Hypertension |
| Q38642429 | Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects |
| Q38779774 | Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations. |
| Q37450106 | Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil |
| Q64881402 | Rho signaling pathway enhances proliferation of PASMCs by suppressing nuclear translocation of Smad1 in PAH. |
| Q57166510 | TGF-β and BMPR2 Signaling in PAH: Two Black Sheep in One Family |
| Q37997101 | Targeting RhoA/ROCK pathway in pulmonary arterial hypertension |
| Q26992278 | The molecular genetics and cellular mechanisms underlying pulmonary arterial hypertension |
| Q54527080 | The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally. |
| Q46682354 | Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension |
Search more.